Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
07:00am, Wednesday, 01'st May 2024
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that 14 abstracts, 11 of which are oral presentations, will be presented at the Associatio
Apellis Pharmaceuticals stock has lost 40% in 2024: buy the dip?
12:28pm, Tuesday, 30'th Apr 2024
Apellis Pharmaceuticals Inc (NASDAQ: APLS) is down nearly 40% versus its year-to-date high but a Mizuho analyst does not see it as an opportunity to buy per se. Mizuho remains ‘neutral' on Apellis P
Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
11:06am, Tuesday, 30'th Apr 2024
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
07:15am, Friday, 26'th Apr 2024
WALTHAM, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the European Medicines Agency (EMA) has reset the review of the marketing authoriza
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
07:00am, Tuesday, 23'rd Apr 2024
WALTHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 04'th Apr 2024
WALTHAM, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant d
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
07:00am, Monday, 01'st Apr 2024
WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the 23rd Annual Needham Virtual Healthcar
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
07:00am, Monday, 11'th Mar 2024
WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief Medi
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 06'th Mar 2024
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant d
Apellis (APLS) Q4 Earnings Miss, Revenues Meet Estimates
10:10am, Wednesday, 28'th Feb 2024
Apellis' (APLS) fourth-quarter 2023 bottom line misses estimates, while the top line meets the same. The newly approved product, Syfovre, drives year-over-year sales.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Earnings: What Key Metrics Have to Say
10:36am, Tuesday, 27'th Feb 2024
While the top- and bottom-line numbers for Apellis Pharmaceuticals, Inc. (APLS) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Lags Revenue Estimates
09:21am, Tuesday, 27'th Feb 2024
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $1.50 per share a year ago.
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
07:05am, Tuesday, 27'th Feb 2024
WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its fourth quarter and full year 2023 financial results and business highlights.
5 Stocks to Buy That Are Poised to Beat on Earnings This Week
08:41am, Monday, 26'th Feb 2024
We have narrowed our search to five stocks that are poised to beat on earnings this week. These are: HEi, CEG, IPAR, APLS, PCVX.
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
07:00am, Monday, 26'th Feb 2024
WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following March investor conferences:
